- Home
- UA vs KNSA Comparison
UA vs KNSA Comparison
Compare UA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UA | KNSA |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United Kingdom |
| Employees | 14400 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | UA | KNSA |
|---|---|---|
| Price | $6.14 | $47.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $55.29 |
| AVG Volume (30 Days) | ★ 2.3M | 544.1K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $38.01 |
| Revenue Next Year | $1.57 | $17.42 |
| P/E Ratio | ★ N/A | $62.57 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $3.95 | $18.40 |
| 52 Week High | $7.91 | $50.03 |
Technical Indicators
Market Signals| Indicator | UA | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 53.56 |
| Support Level | $5.86 | $39.96 |
| Resistance Level | $6.44 | $48.14 |
| Average True Range (ATR) | 0.26 | 1.88 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 87.70 | 54.71 |
Price Performance
Historical ComparisonAbout UA Under Armour Inc. Class C
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.